Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis (VAART)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Background:
The safety of vaccination in patients with autoimmune diseases using immune suppressive therapy is often discussed. Previous studies in Juvenile Idiopathic Arthritis (JIA) patients showed no increase in disease activity after immunisation with dead vaccines. The safety of the live attenuated Measles, Mumps, Rubella (MMR) vaccination was assessed retrospectively in JIA patients and no increase in disease activity was found. However, this must be prospectively confirmed. In addition, it is unknown whether vaccination is effective, since the immune response to vaccination may be diminished due to immunosuppressive therapy for the underlying disease. Finally, the influence of MMR vaccination on the immune system of JIA patients has not been studied. Among others, regulatory T-cells (Tregs) should control the immune response and prevent destructive autoimmune responses after environmental triggers such as vaccination.
Objective:
The aim of the present study is to investigate the safety and efficacy of the MMR booster vaccination and its influence on immune regulatory mechanisms in children with Juvenile Idiopathic Arthritis.
Method:
JIA patients aged 4 to 8 years and treated by the pediatric rheumatology units from various University Medical Centers in the Netherlands, are asked to participate in a prospective study. In the Netherlands, measles-mumps-rubella (MMR) vaccination is included in the National Vaccination Program and is normally administered at age 9. Included patients will be randomised for early vaccination (age group 4 to 8yr at entry of the study) or at age 9 as is routinely done according to the National Vaccination Program. Prior to and after vaccination the investigators will assess disease activity and collect blood.
Outcome:
During a 12 month follow-up period the investigators will register disease activity and side-effects at different moments in time to determine safety of vaccination. The efficacy of the vaccine will be studied according to antibody levels and function against measles, mumps and rubella in the blood. Tregs will be isolated and their functionality will be determined using the blood cells collected during follow-up. This enables us to study the role influence of vaccination on regulatory mechanisms in our immune system.
| Condition | Intervention | Phase |
|---|---|---|
|
Arthritis, Juvenile Rheumatoid |
Biological: Measles, Mumps, Rubella vaccination |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label |
| Official Title: | Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine |
- JIA disease activity, defined by the core set criteria for JIA and number of flares [ Time Frame: baseline and after 3, 6,9,12 months ] [ Designated as safety issue: Yes ]
- Immunological reaction to MMR vaccination and regulatory mechanisms induced by MMR, measured by number and function of MMR-specific T cells and cytokine profiles [ Time Frame: baseline, 3 and 12 months ] [ Designated as safety issue: No ]immunogenicity measuring antibody titers and T cell profileration to rubella virus
| Enrollment: | 140 |
| Study Start Date: | May 2008 |
| Estimated Study Completion Date: | May 2012 |
| Estimated Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Measles, mumps, rubella booster vaccination within 3 months after randomisation
|
Biological: Measles, Mumps, Rubella vaccination
Dosage: 1 dose MMR vaccine, containing 5000 p.f.u. (plaque forming unit) life attenuated mumps virus (Jeryl-Lynn-strain), 1000 p.f.u. life attenuated measles virus (Moraten-strain) and 1000 p.f.u. life attenuated rubella virus (Wistar RA 27/3-strain) + 0.5 ml solution fluid Dosage form: subcutaneously frequency: once
Other Name: RVG 17654, BMR-NVI
|
|
No Intervention: 2
Booster vaccination performed by regular health authorities at age 9; at least 1 year after randomisation
|
Eligibility| Ages Eligible for Study: | 4 Years to 9 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- all subtypes of JIA according to ILAR criteria
- ages 4 to 9 (before the scheduled booster, normally administered at age 9 in the Netherlands)
- 5 healthy adults (aged 18 to 65y)
Exclusion Criteria:
- use of Infliximab (Remicade, anti-Tumor Necrosis Factor (TNF) alpha therapy).
- primary immunodeficiency
- fever less than 48 hour prior to vaccination (vaccination will be postponed for 1 month)
- evidence of viral or bacterial infection less than 48hours prior to vaccination (vaccination will be postponed for 1 month)
- methylprednisolone pulse therapy less than 1 month prior to vaccination (vaccination will be postponed for 1 month)
- transfusion of blood or blood products (e.g. intravenous immunoglobulins (IVIG)) in the 3 months prior to vaccination (vaccination will be postponed for 3 months)
Contacts and Locations| Netherlands | |
| Academic hospital Maastricht | |
| Maastricht, Limburg, Netherlands, 6202 AZ | |
| VU University Medical Center Amsterdam | |
| Amsterdam, Netherlands, 1007 MB | |
| University Medical Center Groningen, Beatrix Children's Hospital | |
| Groningen, Netherlands, 9700 RB | |
| Erasmus Medical Center Rotterdam; sophia Children's Hospital | |
| Rotterdam, Netherlands, 3000 CB | |
| University Medical Center Utrecht, Wilhelmina Children's Hospital | |
| Utrecht, Netherlands, 3508 AB | |
| Principal Investigator: | Nico M. Wulffraat, MD;PhD | UMC Utrecht |
More Information
Publications:
| Responsible Party: | N.M. Wulffraat, associate professor, UMC Utrecht |
| ClinicalTrials.gov Identifier: | NCT00731965 History of Changes |
| Other Study ID Numbers: | VAART, ISRCTN12271664 |
| Study First Received: | August 6, 2008 |
| Last Updated: | August 23, 2011 |
| Health Authority: | Netherlands: Independent Ethics Committee Netherlands: Medical Ethics Review Committee (METC) Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Keywords provided by UMC Utrecht:
|
Arthritis, Juvenile Rheumatoid Measles-Mumps-Rubella Vaccine Serology Lymphocytes |
Additional relevant MeSH terms:
|
Arthritis, Juvenile Rheumatoid Arthritis Measles Mumps Rubella Joint Diseases Musculoskeletal Diseases Morbillivirus Infections Paramyxoviridae Infections Mononegavirales Infections RNA Virus Infections Virus Diseases Rubulavirus Infections |
Parotitis Parotid Diseases Salivary Gland Diseases Mouth Diseases Stomatognathic Diseases Rubivirus Infections Togaviridae Infections Arthritis, Rheumatoid Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013